Epigenetics in Systemic Lupus Erythematosus: Leading the Way for Specific Therapeutic Agents

Overview

Journal Int J Clin Rheumtol

Publisher Future Medicine

Specialty Rheumatology

Date 2011 Dec 21

PMID 22184503

Citations 28

Authors

Matlock A Jeffries

Amr H Sawalha

Affiliations

Soon will be listed here.

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder of an unclearly determined etiology. Past studies, both epidemiological and biological, have implicated epigenetic influences in disease etiology and pathogenesis. Epigenetics describes changes in gene expression not linked to alterations in the underlying genomic sequence, and is most often typified by three modifications: methylation of DNA, addition of various side chains to histone groups and transcriptional regulation via short ncRNA sequences. The purpose of this article is to review the most important advances that link epigenetic changes to lupus. The contribution of DNA methylation changes to lupus pathogenesis is discussed. These include the role of apoptotic DNA, ultraviolet radiation, endogenous retroviruses, dietary contributions and aging. Hypomethylation of specific genes overexpressed in lupus T cells such as ITGAL (CD11a), CD40LG (CD40L), TNFSF7 (CD70), KIR2DL4 and PRF1 (perforin), and CD5 in lupus B cells seem to play an important role. Moreover, histone modifications such as increased global H4 acetylation in monocytes are highly associated with SLE. NcRNAs, especially miR-21, miR-148a and miR-126, control other elements of epigenetic regulation; particularly, transcription of the maintenance DNA methylation enzyme DNMT1. Epigenetic contributions to SLE etiology have been well established, but much is still unknown. Epigenome-wide studies coupled with functional analysis of the epigenomic changes discovered will uncover novel pathways important in disease pathogenesis. Epigenetic therapies for SLE may be feasible in the future, particularly if they are designed to target specific regions within the genome.

Citing Articles

Human immune system: Exploring diversity across individuals and populations.

Hoang Nguyen K, Le N, Nguyen P, Nguyen H, Hoang D, Huynh C Heliyon. 2025; 11(2):e41836.

PMID: 39911431 PMC: 11795082. DOI: 10.1016/j.heliyon.2025.e41836.

CMPK2 Promotes CD4 T Cell Activation and Apoptosis through Modulation of Mitochondrial Dysfunction in Systemic Lupus Erythematosus.

Tan Y, Jiang G, Meng X, Lu Z, Yan-Ma , Li J Cell Biochem Biophys. 2024; 82(4):3547-3557.

PMID: 39078538 DOI: 10.1007/s12013-024-01443-1.

Myeloid-derived suppressor cell: A crucial player in autoimmune diseases.

Xu D, Li C, Xu Y, Huang M, Cui D, Xie J Front Immunol. 2022; 13:1021612.

PMID: 36569895 PMC: 9780445. DOI: 10.3389/fimmu.2022.1021612.

Sex bias in systemic lupus erythematosus: a molecular insight.

Bose M, Jefferies C Immunometabolism (Cobham). 2022; 4(3):e00004.

PMID: 35966636 PMC: 9358995. DOI: 10.1097/IN9.0000000000000004.

Cardiovascular risk in the postnatal life of children born to women with systemic lupus erythematous.

Sandoval-Valdez D, Silveira L, Rodriguez E Arch Cardiol Mex. 2022; 92(4):522-529.

PMID: 35358379 PMC: 9681509. DOI: 10.24875/ACM.21000063.

References

Richardson B . Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum Immunol. 1986; 17(4):456-70. DOI: 10.1016/0198-8859(86)90304-6. View

Shuttleworth S, Bailey S, Townsend P . Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010; 11(11):1430-8. DOI: 10.2174/1389450111009011430. View

Herrmann M, Hagenhofer M, Kalden J . Retroviruses and systemic lupus erythematosus. Immunol Rev. 1996; 152:145-56. DOI: 10.1111/j.1600-065x.1996.tb00914.x. View

Zhao M, Wu X, Zhang Q, Luo S, Liang G, Su Y . RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res Ther. 2011; 12(6):R227. PMC: 3046540. DOI: 10.1186/ar3214. View

Luo Y, Zhang X, Zhao M, Lu Q . DNA demethylation of the perforin promoter in CD4(+) T cells from patients with subacute cutaneous lupus erythematosus. J Dermatol Sci. 2009; 56(1):33-6. DOI: 10.1016/j.jdermsci.2009.06.010. View

Valiante N, Uhrberg M, Shilling H, Arnett K, DAndrea A, Phillips J . Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1998; 7(6):739-51. DOI: 10.1016/s1074-7613(00)80393-3. View

Gorelik G, Fang J, Wu A, Sawalha A, Richardson B . Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol. 2007; 179(8):5553-63. DOI: 10.4049/jimmunol.179.8.5553. View

Gaipl U, Kuhn A, Sheriff A, Munoz L, Franz S, Voll R . Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun. 2006; 9:173-87. DOI: 10.1159/000090781. View

Perez P, Goicovich E, Alliende C, Aguilera S, Leyton C, Molina C . Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 2001; 43(12):2807-17. DOI: 10.1002/1529-0131(200012)43:12<2807::AID-ANR22>3.0.CO;2-M. View

10.

Nilsson B, Skogh T, Ernerudh J, Johansson B, Lofgren S, Wikby A . Antinuclear antibodies in the oldest-old women and men. J Autoimmun. 2006; 27(4):281-8. DOI: 10.1016/j.jaut.2006.10.002. View

11.

Zhang Z, Song L, Maurer K, Petri M, Sullivan K . Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun. 2009; 11(2):124-33. PMC: 2832080. DOI: 10.1038/gene.2009.66. View

12.

Deng C, Kaplan M, Yang J, Ray D, Zhang Z, McCune W . Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum. 2001; 44(2):397-407. DOI: 10.1002/1529-0131(200102)44:2<397::AID-ANR59>3.0.CO;2-N. View

13.

Muller S, Briand J, Van Regenmortel M . Presence of antibodies to ubiquitin during the autoimmune response associated with systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1988; 85(21):8176-80. PMC: 282390. DOI: 10.1073/pnas.85.21.8176. View

14.

Scheinbart L, Johnson M, Gross L, Edelstein S, Richardson B . Procainamide inhibits DNA methyltransferase in a human T cell line. J Rheumatol. 1991; 18(4):530-4. View

15.

Liu Y, Kuick R, Hanash S, Richardson B . DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol. 2008; 130(2):213-24. PMC: 2655730. DOI: 10.1016/j.clim.2008.08.009. View

16.

Ford P, Durham A, Russell R, Gordon F, Adcock I, Barnes P . Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010; 137(6):1338-44. DOI: 10.1378/chest.09-2363. View

17.

Ogasawara H, Naito T, Kaneko H, Hishikawa T, Sekigawa I, Hashimoto H . Quantitative analyses of messenger RNA of human endogenous retrovirus in patients with systemic lupus erythematosus. J Rheumatol. 2001; 28(3):533-8. View

18.

Dai R, Zhang Y, Khan D, Heid B, Caudell D, Crasta O . Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS One. 2010; 5(12):e14302. PMC: 3000827. DOI: 10.1371/journal.pone.0014302. View

19.

Blasi F, Toniolo D . DNA methylation and X-chromosome inactivation. Mol Biol Med. 1983; 1(2):271-4. View

20.

Zhao M, Sun Y, Gao F, Wu X, Tang J, Yin H . Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells. J Autoimmun. 2010; 35(1):58-69. DOI: 10.1016/j.jaut.2010.02.002. View